Guggenheim Reiterates Buy on Neumora Therapeutics, Maintains $14 Price Target

Neumora Therapeutic

Neumora Therapeutic

NMRA

0.00

Guggenheim analyst Yatin Suneja reiterates Neumora Therapeutics (NASDAQ: NMRA) with a Buy and maintains $14 price target.